Attributes | Values |
---|
rdf:type
| |
Description
| - The MM-015 trial assessed lenalidomide-based therapy on health-related quality of life. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and treatment end. Health-related quality of life improved in all treatment groups during induction therapy. More patients receiving lenalidomide maintenance achieved minimally important differences (P<0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance improves health-related quality of life in patients with newly diagnosed multiple myeloma.
- The MM-015 trial assessed lenalidomide-based therapy on health-related quality of life. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and treatment end. Health-related quality of life improved in all treatment groups during induction therapy. More patients receiving lenalidomide maintenance achieved minimally important differences (P<0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance improves health-related quality of life in patients with newly diagnosed multiple myeloma. (en)
|
Title
| - Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
- Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial (en)
|
skos:prefLabel
| - Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
- Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial (en)
|
skos:notation
| - RIV/61988987:17110/12:A13017JD!RIV13-MSM-17110___
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61988987:17110/12:A13017JD
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Health-related quality of life; multiple myeloma; lenalidomide; QLQ-C30; QLQ-MY20 (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Hájek, Roman
- Zhang, J.
- Dimopoulos, M. A.
- Delforge, M.
- Kropff, M.
- Lewis, P.
- Mei, J.
- Nixon, A.
- Palumbo, A.
- Petrucci, MT
|
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |
is http://linked.open...avai/riv/vysledek
of | |